Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 study group

Alessandro Testori, Jon Richards, Eric Whitman, G. Bruce Mann, Jose Lutzky, Luis Camacho, Giorgio Parmiani, Giulio Tosti, John M. Kirkwood, Axel Hoos, Lianng Yuh, Renu Gupta, Pramod K. Srivastava

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Purpose: To assess the antitumor activity of vitespen (autologous, tumor- derived heat shock protein gp96 peptide complexes) by determining whether patients with stage IV melanoma treated with vitespen experienced longer overall survival than patients treated with physician's choice. Patients and Methods: Patients (N = 322) were randomly assigned 2:1 to receive vitespen or physician's choice (PC) of a treatment containing one or more of the following: dacarbazine, temozolomide, interleukin-2, or complete tumor resection. This open-label trial was conducted at 71 centers worldwide. Patients were monitored for safety and overall survival. Results: Therapy with vitespen is devoid of significant toxicity. Patients randomly assigned to the vitespen arm received variable number of injections (range, 0 to 87; median, 6) in part because of the autologous nature of vitespen therapy. Intention-to-treat analysis showed that overall survival in the vitespen arm is statistically indistinguishable from that in the PC arm. Exploratory landmark analyses show that patients in the M1a and M1b substages receiving a larger number of vitespen immunizations survived longer than those receiving fewer such treatments. Such difference was not detected for substage M1c patients. Conclusion: These results are consistent with the immunologic mechanism of action of vitespen, indicating delayed onset of clinical activity after exposure to the vaccine. The results suggest patients with M1a and M1b disease who are able to receive 10 or more doses of vitespen as the candidate population for a confirmatory study.

Original languageEnglish (US)
Pages (from-to)955-962
Number of pages8
JournalJournal of Clinical Oncology
Volume26
Issue number6
DOIs
StatePublished - Feb 20 2008

Fingerprint

Subunit Vaccines
Heat-Shock Proteins
Melanoma
Physicians
Neoplasms
Therapeutics
temozolomide
Survival
Dacarbazine
Intention to Treat Analysis
Interleukin-2
Immunization
Vaccines
Safety
Peptides
Injections

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Testori, Alessandro ; Richards, Jon ; Whitman, Eric ; Mann, G. Bruce ; Lutzky, Jose ; Camacho, Luis ; Parmiani, Giorgio ; Tosti, Giulio ; Kirkwood, John M. ; Hoos, Axel ; Yuh, Lianng ; Gupta, Renu ; Srivastava, Pramod K. / Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma : The C-100-21 study group. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 6. pp. 955-962.
@article{6971febc85bb4c97bb4709d5a48e4cd5,
title = "Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 study group",
abstract = "Purpose: To assess the antitumor activity of vitespen (autologous, tumor- derived heat shock protein gp96 peptide complexes) by determining whether patients with stage IV melanoma treated with vitespen experienced longer overall survival than patients treated with physician's choice. Patients and Methods: Patients (N = 322) were randomly assigned 2:1 to receive vitespen or physician's choice (PC) of a treatment containing one or more of the following: dacarbazine, temozolomide, interleukin-2, or complete tumor resection. This open-label trial was conducted at 71 centers worldwide. Patients were monitored for safety and overall survival. Results: Therapy with vitespen is devoid of significant toxicity. Patients randomly assigned to the vitespen arm received variable number of injections (range, 0 to 87; median, 6) in part because of the autologous nature of vitespen therapy. Intention-to-treat analysis showed that overall survival in the vitespen arm is statistically indistinguishable from that in the PC arm. Exploratory landmark analyses show that patients in the M1a and M1b substages receiving a larger number of vitespen immunizations survived longer than those receiving fewer such treatments. Such difference was not detected for substage M1c patients. Conclusion: These results are consistent with the immunologic mechanism of action of vitespen, indicating delayed onset of clinical activity after exposure to the vaccine. The results suggest patients with M1a and M1b disease who are able to receive 10 or more doses of vitespen as the candidate population for a confirmatory study.",
author = "Alessandro Testori and Jon Richards and Eric Whitman and Mann, {G. Bruce} and Jose Lutzky and Luis Camacho and Giorgio Parmiani and Giulio Tosti and Kirkwood, {John M.} and Axel Hoos and Lianng Yuh and Renu Gupta and Srivastava, {Pramod K.}",
year = "2008",
month = "2",
day = "20",
doi = "10.1200/JCO.2007.11.9941",
language = "English (US)",
volume = "26",
pages = "955--962",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma : The C-100-21 study group. / Testori, Alessandro; Richards, Jon; Whitman, Eric; Mann, G. Bruce; Lutzky, Jose; Camacho, Luis; Parmiani, Giorgio; Tosti, Giulio; Kirkwood, John M.; Hoos, Axel; Yuh, Lianng; Gupta, Renu; Srivastava, Pramod K.

In: Journal of Clinical Oncology, Vol. 26, No. 6, 20.02.2008, p. 955-962.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma

T2 - The C-100-21 study group

AU - Testori, Alessandro

AU - Richards, Jon

AU - Whitman, Eric

AU - Mann, G. Bruce

AU - Lutzky, Jose

AU - Camacho, Luis

AU - Parmiani, Giorgio

AU - Tosti, Giulio

AU - Kirkwood, John M.

AU - Hoos, Axel

AU - Yuh, Lianng

AU - Gupta, Renu

AU - Srivastava, Pramod K.

PY - 2008/2/20

Y1 - 2008/2/20

N2 - Purpose: To assess the antitumor activity of vitespen (autologous, tumor- derived heat shock protein gp96 peptide complexes) by determining whether patients with stage IV melanoma treated with vitespen experienced longer overall survival than patients treated with physician's choice. Patients and Methods: Patients (N = 322) were randomly assigned 2:1 to receive vitespen or physician's choice (PC) of a treatment containing one or more of the following: dacarbazine, temozolomide, interleukin-2, or complete tumor resection. This open-label trial was conducted at 71 centers worldwide. Patients were monitored for safety and overall survival. Results: Therapy with vitespen is devoid of significant toxicity. Patients randomly assigned to the vitespen arm received variable number of injections (range, 0 to 87; median, 6) in part because of the autologous nature of vitespen therapy. Intention-to-treat analysis showed that overall survival in the vitespen arm is statistically indistinguishable from that in the PC arm. Exploratory landmark analyses show that patients in the M1a and M1b substages receiving a larger number of vitespen immunizations survived longer than those receiving fewer such treatments. Such difference was not detected for substage M1c patients. Conclusion: These results are consistent with the immunologic mechanism of action of vitespen, indicating delayed onset of clinical activity after exposure to the vaccine. The results suggest patients with M1a and M1b disease who are able to receive 10 or more doses of vitespen as the candidate population for a confirmatory study.

AB - Purpose: To assess the antitumor activity of vitespen (autologous, tumor- derived heat shock protein gp96 peptide complexes) by determining whether patients with stage IV melanoma treated with vitespen experienced longer overall survival than patients treated with physician's choice. Patients and Methods: Patients (N = 322) were randomly assigned 2:1 to receive vitespen or physician's choice (PC) of a treatment containing one or more of the following: dacarbazine, temozolomide, interleukin-2, or complete tumor resection. This open-label trial was conducted at 71 centers worldwide. Patients were monitored for safety and overall survival. Results: Therapy with vitespen is devoid of significant toxicity. Patients randomly assigned to the vitespen arm received variable number of injections (range, 0 to 87; median, 6) in part because of the autologous nature of vitespen therapy. Intention-to-treat analysis showed that overall survival in the vitespen arm is statistically indistinguishable from that in the PC arm. Exploratory landmark analyses show that patients in the M1a and M1b substages receiving a larger number of vitespen immunizations survived longer than those receiving fewer such treatments. Such difference was not detected for substage M1c patients. Conclusion: These results are consistent with the immunologic mechanism of action of vitespen, indicating delayed onset of clinical activity after exposure to the vaccine. The results suggest patients with M1a and M1b disease who are able to receive 10 or more doses of vitespen as the candidate population for a confirmatory study.

UR - http://www.scopus.com/inward/record.url?scp=39749186213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749186213&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.11.9941

DO - 10.1200/JCO.2007.11.9941

M3 - Article

C2 - 18281670

AN - SCOPUS:39749186213

VL - 26

SP - 955

EP - 962

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -